Ten-year safety of pluripotent stem cell transplantation in acute thoracic spinal cord injury
Summary
This study provides crucial first-in-human safety data supporting the pursuit of future human embryonic stem cell-derived therapies. While we cannot exclude the possibility of future adverse events, the experience in this trial provides evidence that this cell type can be well tolerated by patients, with an event-free period of up to 10 years. Based on the safety profile of LCTOPC1 obtained in this study, a cervical dose escalation trial was initiated (NCT02302157).
| Authors | McKenna SL, Ehsanian R, Liu CY, Steinberg GK, Jones L, Lebkowski JS, Wirth E, Fessler RG |
|---|---|
| Journal | Journal of neurosurgery. Spine |
| Publication Date | 2022 Sep 1;37(3):321-330 |
| PubMed | 35364569 |
| DOI | 10.3171/2021.12.spine21622 |
Research Projects
Cell Lines
- (none)